Peptonic Medical receives approval for its clinical Phase 2b study
Stockholm 24th March 2016. - Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that it has received approval from the Swedish Medical Products Agency to start the planned Phase 2b study. Previously Peptonic has received approval from the Ethical Vetting Board.“Albeit expected, we are very pleased with having received these approvals. This means that we are on track according to the time table and that the first patients are expected to enter the study in May. ”, says Johan Inborr, CEO of Peptonic. For more